FDA Says Shortage of GLP-1 Tirzepatide Is Over
1 day ago · HealthDay News — The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the diabetes/weight-loss medication tirzepatide is over. Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).
FDA Announced Removal of Tirzepatide from the Drug Shortage …
5 hours ago · On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and weight-loss tirzepatide injection products (Mounjaro and ...
FDA says tirzepatide shortage is over after taking a second look - NBC News
Dec 19, 2024 · The Food and Drug Administration said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs...
Compounding pharmacies can resume making tirzepatide as FDA ... - NBC News
Oct 14, 2024 · The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide as it reconsiders whether the drug is in shortage.
FDA confirms end of Eli Lilly’s tirzepatide shortage after re ...
Dec 20, 2024 · The FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade group for compounding pharmacists, pushed the FDA to reconsider. In a letter sent to Eli Lilly on 19 December, the agency confirmed the same October outcome had been reached after a re-evaluation.
FDA clarifies policies for compounders as national GLP-1 supply …
Oct 22, 2024 · The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved.
FDA says this weight loss drug shortage is over, but ... - CBS News
Oct 23, 2024 · For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's shortage was anything but welcome news. "I had an anxiety attack," said...
FDA Says Compounded Tirzepatide Must Exit the Market
Dec 19, 2024 · Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is the only once-weekly dual GIP/GLP-1 receptor agonist on the market and ...
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
Oct 3, 2024 · The Food and Drug Administration on Wednesday declared an end to the two-year shortage of tirzepatide, the substance in the popular weight-loss medication Zepbound and the diabetes drug...
Tirzepatide Shortage Resolved? FDA Says Yes, Compounders No
Oct 7, 2024 · Tirzepatide injection (Zepbound, Mounjaro) is officially off the FDA's drug shortage list, meaning compounders can no longer prepare and dispense the drug.